Peter Fernandes
Chairman at The Pulmonary Vascular Research Institute
Net worth: 1 940 $ as of 2024-03-30
Profile
Peter Fernandes is currently the Co-Chairman at The Pulmonary Vascular Research Institute.
He previously worked as the Vice President-Global Regulatory Affairs at Ikaria, Inc. from 2012 to 2015, Head-Regulatory Affairs & Quality Assurance at OptiNose, Inc. from 2010 to 2012, VP-Regulatory Affairs & Quality Assurance at ALTANA Pharma US, Inc. from 2005 to 2007, and Vice President-US Drug Regulatory Affairs at Novartis Pharmaceuticals AG from 2007 to 2010.
He is also currently the Chief Executive, Financial & Accounting Officer at Bellerophon Therapeutics, Inc. starting from 2015.
Mr. Fernandes received his graduate degree from The Grant Government Medical College in 1982 and his undergraduate degree from Principal K.
M.
Kundnani College of Pharmacy.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-10-30 | 34,649 ( 0.28% ) | 1 940 $ | 2024-03-30 |
Peter Fernandes active positions
| Companies | Position | Start |
|---|---|---|
The Pulmonary Vascular Research Institute
 The Pulmonary Vascular Research Institute Miscellaneous Commercial ServicesCommercial Services The Pulmonary Vascular Research Institute operates as a medical research charity. The non-profit company is based in Canterbury, UK. | Chairman | - |
Former positions of Peter Fernandes
| Companies | Position | End |
|---|---|---|
| BELLEROPHON THERAPEUTICS, INC. | Chief Executive Officer | 2023-11-14 |
| IKARIA, INC. | General Counsel | 2015-04-30 |
| OPTINOSE, INC. | General Counsel | 2012-08-31 |
| Novartis Pharmaceuticals AG | Corporate Officer/Principal | 2010-09-30 |
ALTANA Pharma US, Inc.
 ALTANA Pharma US, Inc. Pharmaceuticals: MajorHealth Technology ALTANA Pharma US, Inc. develops respiratory and gastrointestinal products. The company is headquartered in Florham Park, NJ. | General Counsel | 2007-09-30 |
Training of Peter Fernandes
| The Grant Government Medical College | Graduate Degree |
| Principal K. M. Kundnani College of Pharmacy | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| OPTINOSE, INC. | Health Technology |
| BELLEROPHON THERAPEUTICS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Ikaria, Inc.
 Ikaria, Inc. BiotechnologyHealth Technology Ikaria, Inc. operates as a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the medical needs of critically ill patients. It offers INOMAX for inhalation, which is used to treat newborns suffering from hypoxic respiratory failure, and is making a major impact on the critical care environment. The company was founded on August 18, 2006 and is headquartered in Clinton, NJ. | Health Technology |
ALTANA Pharma US, Inc.
ALTANA Pharma US, Inc. Pharmaceuticals: MajorHealth Technology ALTANA Pharma US, Inc. develops respiratory and gastrointestinal products. The company is headquartered in Florham Park, NJ. | Health Technology |
The Pulmonary Vascular Research Institute
The Pulmonary Vascular Research Institute Miscellaneous Commercial ServicesCommercial Services The Pulmonary Vascular Research Institute operates as a medical research charity. The non-profit company is based in Canterbury, UK. | Commercial Services |
| Novartis Pharmaceuticals AG |
- Stock Market
- Insiders
- Peter Fernandes
